Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven

NCT06030089 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

OTHER: Pharmacokinetic sampling
OTHER: Vital status determination
OTHER: Toxicity assessments
DRUG: Venetoclax and azacitidine combination

Sponsor

Centre Hospitalier Universitaire de Nice